{
  "id": "5e29f959aa19d74431000004",
  "type": "yesno",
  "question": "Can LB-100 sensitize ovarian carcinoma to cisplatin?",
  "ideal_answer": "Yes, LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25376608"
  ],
  "snippets": [
    {
      "text": "The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376608",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "LB100 sensitized ovarian carcinoma lines to cisplatin-mediated cell death. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376608",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our results suggest that LB100 sensitizes ovarian cancer cells to cisplatin in vitro and in vivo by modulation of the DDR pathway and cell-cycle checkpoint abrogation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25376608",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}